27 August 2025 - PharmaEssentia Korea announced on Wednesday that Besremi (ropeginterferon alfa-2b), a treatment for polycythemia vera, will be covered by national health insurance as a second-line therapy for polycythemia vera, starting 1 September 2025, following the Ministry of Health and Welfare's official notice.

The reimbursement applies to patients who are intolerant or unresponsive to hydroxyurea and who either do not have splenomegaly or have a spleen size of 17 cm or smaller. The treatment duration is up to three years, and administration is discontinued if a complete haematologic response is not achieved by the 12th month.

Read Korea Biomedical Review article